TrimRX
US$ 20.52
boehringer glp-1 Boehringer, Zealand's MASH Data 'Unintentionally' Published by Medical Congress Website GLP-1 2.0: Where the Next
Description
This blog is part of an ongoing series on A Brave New World: Therapeutic Area Deep Dives
Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus
Do not start a GLP-1 receptor agonist in a patient with a prior diagnosis of gastroparesis
The rate of metabolic bariatric surgery decreased from 2022 to 2023, whereas the use of GLP-1 receptor agonists as anti-obesity medications grew over twofold, a research letter showed